Europe Medical Foods Market Size, Share & Trends Analysis Report By Route Of Administration (Oral, Enteral), By Product (Powder, Pills), By Application, By Module, By Sales Channel, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Europe Medical Foods Market Growth & Trends
The Europe medical foods market size is expected treach USD 7.31 billion by 2030, registering a CAGR of 2.94% from 2025 t2030, according ta new report by Grand View Research, Inc. The ever-increasing burden of chronic diseases and the growing geriatric population across Europe are primary reasons for the market tflourish. In 2021, the oral route of administration accounted for the largest revenue share of 69.5%. Ease of use and high availability of medical foods in this form has contributed tthe high revenue. The enteral route of administration is expected tregister the fastest growth. This can be attributed tthe growing geriatric population suffering from chronic diseases whare unable tconsume food orally. The enteral route of administration seems tbe the preferred way of administrating nutrients through medical foods tthe specific needs of geriatric patients.
In the product type, the powder formulations held the largest revenue share in 2024. Owing tthe vast product portfolios available in this formulation this segment has grown ta large extent. Powder formulations include nutrient mixes, protein shakes, and infant feeding formulas. The highest growth was registered by the liquid formulations due tthe diversification of product portfolios of the key players in the medical foods industry. Cancer had the largest revenue share in 2024 in the applications segment. Nutritional deficiency in cancer patients is a major concern and can be managed through proper nutrient management via medical foods and is a major factor in its growth. The fastest-growing sub-segment is diabetic neuropathy, high prevalence, and has been a key driver for its fast growth.
The largest sales channel for 2024 was direct-to-consumer, owing tthe emerged as a significant channel within the market, providing opportunities for manufacturers tengage directly with consumers and tailor their offerings tmeet specific health needs.
Europe Medical Foods Market Report Highlights
Europe Medical Foods Market Growth & Trends
The Europe medical foods market size is expected treach USD 7.31 billion by 2030, registering a CAGR of 2.94% from 2025 t2030, according ta new report by Grand View Research, Inc. The ever-increasing burden of chronic diseases and the growing geriatric population across Europe are primary reasons for the market tflourish. In 2021, the oral route of administration accounted for the largest revenue share of 69.5%. Ease of use and high availability of medical foods in this form has contributed tthe high revenue. The enteral route of administration is expected tregister the fastest growth. This can be attributed tthe growing geriatric population suffering from chronic diseases whare unable tconsume food orally. The enteral route of administration seems tbe the preferred way of administrating nutrients through medical foods tthe specific needs of geriatric patients.
In the product type, the powder formulations held the largest revenue share in 2024. Owing tthe vast product portfolios available in this formulation this segment has grown ta large extent. Powder formulations include nutrient mixes, protein shakes, and infant feeding formulas. The highest growth was registered by the liquid formulations due tthe diversification of product portfolios of the key players in the medical foods industry. Cancer had the largest revenue share in 2024 in the applications segment. Nutritional deficiency in cancer patients is a major concern and can be managed through proper nutrient management via medical foods and is a major factor in its growth. The fastest-growing sub-segment is diabetic neuropathy, high prevalence, and has been a key driver for its fast growth.
The largest sales channel for 2024 was direct-to-consumer, owing tthe emerged as a significant channel within the market, providing opportunities for manufacturers tengage directly with consumers and tailor their offerings tmeet specific health needs.
Europe Medical Foods Market Report Highlights
- Based on route of administration, the oral segment accounted for the largest revenue share of 76.1% in 2024 owing thigh product type availability and ease of administration
- In 2024, the powder formulation segment accounted for the largest revenue share of 35.2% owing tthe majority product portfoliavailable in the market
- By application, the cancer application segment dominated the market with the largest share of 11.7% in 2024
- The institutional sales channel had the largest share, but the online sales channel is expected tgrow at a steady rate owing tthe preference of consumers and key player initiatives for sales through online channels
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.1.1. Route of Administration
1.1.2. Product Type
1.1.3. Application
1.1.4. Module
1.1.5. Sales Channel
1.1.6. Country scope
1.1.7. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database.
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. EUROPE MEDICAL FOODS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Europe Medical Foods Market Analysis Tools
3.3.1. Industry Analysis - Porter’s 5 Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
3.3.3. COVID-19 Impact
CHAPTER 4. EUROPE MEDICAL FOODS MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
4.1. Route of Administration Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Europe Medical Foods Market by Route of Administration Outlook
4.4. Oral
4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5. Enteral
4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 5. EUROPE MEDICAL FOODS MARKET: PRODUCT TYPE ESTIMATES & TREND ANALYSIS
5.1. Product Type Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Europe Medical Foods Market by Product Type Outlook
5.4. Pills
5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.5. Powder
5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.6. Liquid
5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.7. Others (semisolid, semiliquid)
5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 6. EUROPE MEDICAL FOODS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Application Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Europe Medical Foods Market by Application Outlook
6.4. Chronic Kidney Disease
6.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5. Minimal Hepatic Encephalopathy
6.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.6. Chemotherapy Induced Diarrhea
6.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.7. Pathogen Related Infections
6.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.8. Diabetic Neuropathy
6.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.9. ADHD
6.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.10. Depression
6.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.11. Alzheimer's Disease
6.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.12. Nutritional Deficiency
6.12.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.13. Orphan Diseases
6.13.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.14. Wound Healing
6.14.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.15. Chronic Diarrhea
6.15.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.16. Constipation Relief
6.16.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.17. Protein Booster
6.17.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.18. Dysphagia
6.18.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.19. Pain Management
6.19.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.20. Parkinson's Disease
6.20.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.21. Epilepsy
6.21.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.22. Other Cancer related treatments
6.22.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.23. Severe Protein Allergy
6.23.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.24. Cancer
6.24.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.25. Cachexia
6.25.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.26. Other (debilitating conditions, COPD, etc.)
6.26.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 7. EUROPE MEDICAL FOODS MARKET: MODULES ESTIMATES & TREND ANALYSIS
7.1. Modules Market Share, 2024 & 2030
7.2. Segment Dashboard
7.3. Europe Medical Foods Market by Modules Outlook
7.4. Amino Acid Module
7.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.5. Protein Module
7.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.6. Vitamin & Mineral Modules
7.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.7. Fatty Acid based Modules
7.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.8. Carbohydrate Modules
7.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.9. Fiber Modules
7.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.10. Ketogenic Modules
7.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.11. Peptide based Modules
7.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.12. Hypoallergic Modules
7.12.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.13. Others (Electrolyte Module, etc.)
7.13.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 8. EUROPE MEDICAL FOODS MARKET: SALES CHANNEL ESTIMATES & TREND ANALYSIS
8.1. Sales Channel Market Share, 2024 & 2030
8.2. Segment Dashboard
8.3. Europe Medical Foods Market by Sales Channel Outlook
8.4. DTC Sales Channel
8.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
8.5. Institutional Sales
8.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 9. EUROPE MEDICAL FOODS MARKET: COUNTRY ESTIMATES & TREND ANALYSIS, BY ROUTE OF ADMINISTRATION, BY PRODUCT TYPE, BY APPLICATION, BY MODULE, BY SALES CHANNEL
9.1. Country Market Share Analysis, 2024 & 2030
9.2. Country Market Dashboard
9.3. Country Market Snapshot
9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
9.5. Europe
9.5.1. UK
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework
9.5.1.3. Competitive scenario
9.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
9.5.2. Germany
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework
9.5.2.3. Competitive scenario
9.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
9.5.3. France
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework
9.5.3.3. Competitive scenario
9.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
9.5.4. Italy
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework
9.5.4.3. Competitive scenario
9.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
9.5.5. Spain
9.5.5.1. Key country dynamics
9.5.5.2. Regulatory framework
9.5.5.3. Competitive scenario
9.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
9.5.6. Norway
9.5.6.1. Key country dynamics
9.5.6.2. Regulatory framework
9.5.6.3. Competitive scenario
9.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
9.5.7. Sweden
9.5.7.1. Key country dynamics
9.5.7.2. Regulatory framework
9.5.7.3. Competitive scenario
9.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
9.5.8. Denmark
9.5.8.1. Key country dynamics
9.5.8.2. Regulatory framework
9.5.8.3. Competitive scenario
9.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
9.5.9. Poland
9.5.9.1. Key country dynamics
9.5.9.2. Regulatory framework
9.5.9.3. Competitive scenario
9.5.9.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
9.5.10. Netherlands
9.5.10.1. Key country dynamics
9.5.10.2. Regulatory framework
9.5.10.3. Competitive scenario
9.5.10.4. China market estimates and forecasts 2018 to 2030 (USD Million)
9.5.11. Portugal
9.5.11.1. Key country dynamics
9.5.11.2. Regulatory framework
9.5.11.3. Competitive scenario
9.5.11.4. India market estimates and forecasts 2018 to 2030 (USD Million)
9.5.12. Slovakia
9.5.12.1. Key country dynamics
9.5.12.2. Regulatory framework
9.5.12.3. Competitive scenario
9.5.12.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
9.5.13. Finland
9.5.13.1. Key country dynamics
9.5.13.2. Regulatory framework
9.5.13.3. Competitive scenario
9.5.13.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
9.5.14. Czech Republic
9.5.14.1. Key country dynamics
9.5.14.2. Regulatory framework
9.5.14.3. Competitive scenario
9.5.14.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
9.5.15. Hungary
9.5.15.1. Key country dynamics
9.5.15.2. Regulatory framework
9.5.15.3. Competitive scenario
9.5.15.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
9.5.16. Belgium
9.5.16.1. Key country dynamics
9.5.16.2. Regulatory framework
9.5.16.3. Competitive scenario
9.5.16.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Innovators
10.4. Vendor Landscape
10.4.1. List of key distributors and channel partners
10.4.2. Key customers
10.4.3. Key company market share analysis, 2023
10.4.4. Danone
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Technology Type benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Nestlй
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Technology Type benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Abbott
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Technology Type benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Targeted Medical Pharma Inc. (Physician Therapeutics LLC, a division of the company)
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Technology Type benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Primus Pharmaceuticals Inc.
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Technology Type benchmarking
10.4.8.4. Strategic initiatives
10.4.9. Fresenius Kabi AG
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Technology Type benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Mead Johnson & Company, LLC
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Technology Type benchmarking
10.4.10.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.1.1. Route of Administration
1.1.2. Product Type
1.1.3. Application
1.1.4. Module
1.1.5. Sales Channel
1.1.6. Country scope
1.1.7. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database.
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. EUROPE MEDICAL FOODS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Europe Medical Foods Market Analysis Tools
3.3.1. Industry Analysis - Porter’s 5 Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
3.3.3. COVID-19 Impact
CHAPTER 4. EUROPE MEDICAL FOODS MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
4.1. Route of Administration Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Europe Medical Foods Market by Route of Administration Outlook
4.4. Oral
4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5. Enteral
4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 5. EUROPE MEDICAL FOODS MARKET: PRODUCT TYPE ESTIMATES & TREND ANALYSIS
5.1. Product Type Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Europe Medical Foods Market by Product Type Outlook
5.4. Pills
5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.5. Powder
5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.6. Liquid
5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.7. Others (semisolid, semiliquid)
5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 6. EUROPE MEDICAL FOODS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Application Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Europe Medical Foods Market by Application Outlook
6.4. Chronic Kidney Disease
6.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5. Minimal Hepatic Encephalopathy
6.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.6. Chemotherapy Induced Diarrhea
6.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.7. Pathogen Related Infections
6.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.8. Diabetic Neuropathy
6.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.9. ADHD
6.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.10. Depression
6.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.11. Alzheimer's Disease
6.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.12. Nutritional Deficiency
6.12.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.13. Orphan Diseases
6.13.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.14. Wound Healing
6.14.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.15. Chronic Diarrhea
6.15.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.16. Constipation Relief
6.16.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.17. Protein Booster
6.17.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.18. Dysphagia
6.18.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.19. Pain Management
6.19.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.20. Parkinson's Disease
6.20.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.21. Epilepsy
6.21.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.22. Other Cancer related treatments
6.22.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.23. Severe Protein Allergy
6.23.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.24. Cancer
6.24.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.25. Cachexia
6.25.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.26. Other (debilitating conditions, COPD, etc.)
6.26.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 7. EUROPE MEDICAL FOODS MARKET: MODULES ESTIMATES & TREND ANALYSIS
7.1. Modules Market Share, 2024 & 2030
7.2. Segment Dashboard
7.3. Europe Medical Foods Market by Modules Outlook
7.4. Amino Acid Module
7.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.5. Protein Module
7.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.6. Vitamin & Mineral Modules
7.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.7. Fatty Acid based Modules
7.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.8. Carbohydrate Modules
7.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.9. Fiber Modules
7.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.10. Ketogenic Modules
7.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.11. Peptide based Modules
7.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.12. Hypoallergic Modules
7.12.1. Market estimates and forecast 2018 to 2030 (USD Million)
7.13. Others (Electrolyte Module, etc.)
7.13.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 8. EUROPE MEDICAL FOODS MARKET: SALES CHANNEL ESTIMATES & TREND ANALYSIS
8.1. Sales Channel Market Share, 2024 & 2030
8.2. Segment Dashboard
8.3. Europe Medical Foods Market by Sales Channel Outlook
8.4. DTC Sales Channel
8.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
8.5. Institutional Sales
8.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 9. EUROPE MEDICAL FOODS MARKET: COUNTRY ESTIMATES & TREND ANALYSIS, BY ROUTE OF ADMINISTRATION, BY PRODUCT TYPE, BY APPLICATION, BY MODULE, BY SALES CHANNEL
9.1. Country Market Share Analysis, 2024 & 2030
9.2. Country Market Dashboard
9.3. Country Market Snapshot
9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
9.5. Europe
9.5.1. UK
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework
9.5.1.3. Competitive scenario
9.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
9.5.2. Germany
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework
9.5.2.3. Competitive scenario
9.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
9.5.3. France
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework
9.5.3.3. Competitive scenario
9.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
9.5.4. Italy
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework
9.5.4.3. Competitive scenario
9.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
9.5.5. Spain
9.5.5.1. Key country dynamics
9.5.5.2. Regulatory framework
9.5.5.3. Competitive scenario
9.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
9.5.6. Norway
9.5.6.1. Key country dynamics
9.5.6.2. Regulatory framework
9.5.6.3. Competitive scenario
9.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
9.5.7. Sweden
9.5.7.1. Key country dynamics
9.5.7.2. Regulatory framework
9.5.7.3. Competitive scenario
9.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
9.5.8. Denmark
9.5.8.1. Key country dynamics
9.5.8.2. Regulatory framework
9.5.8.3. Competitive scenario
9.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
9.5.9. Poland
9.5.9.1. Key country dynamics
9.5.9.2. Regulatory framework
9.5.9.3. Competitive scenario
9.5.9.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
9.5.10. Netherlands
9.5.10.1. Key country dynamics
9.5.10.2. Regulatory framework
9.5.10.3. Competitive scenario
9.5.10.4. China market estimates and forecasts 2018 to 2030 (USD Million)
9.5.11. Portugal
9.5.11.1. Key country dynamics
9.5.11.2. Regulatory framework
9.5.11.3. Competitive scenario
9.5.11.4. India market estimates and forecasts 2018 to 2030 (USD Million)
9.5.12. Slovakia
9.5.12.1. Key country dynamics
9.5.12.2. Regulatory framework
9.5.12.3. Competitive scenario
9.5.12.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
9.5.13. Finland
9.5.13.1. Key country dynamics
9.5.13.2. Regulatory framework
9.5.13.3. Competitive scenario
9.5.13.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
9.5.14. Czech Republic
9.5.14.1. Key country dynamics
9.5.14.2. Regulatory framework
9.5.14.3. Competitive scenario
9.5.14.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
9.5.15. Hungary
9.5.15.1. Key country dynamics
9.5.15.2. Regulatory framework
9.5.15.3. Competitive scenario
9.5.15.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
9.5.16. Belgium
9.5.16.1. Key country dynamics
9.5.16.2. Regulatory framework
9.5.16.3. Competitive scenario
9.5.16.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Innovators
10.4. Vendor Landscape
10.4.1. List of key distributors and channel partners
10.4.2. Key customers
10.4.3. Key company market share analysis, 2023
10.4.4. Danone
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Technology Type benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Nestlй
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Technology Type benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Abbott
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Technology Type benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Targeted Medical Pharma Inc. (Physician Therapeutics LLC, a division of the company)
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Technology Type benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Primus Pharmaceuticals Inc.
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Technology Type benchmarking
10.4.8.4. Strategic initiatives
10.4.9. Fresenius Kabi AG
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Technology Type benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Mead Johnson & Company, LLC
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Technology Type benchmarking
10.4.10.4. Strategic initiatives
